New combo therapy aims to keep lung cancer at bay longer
NCT ID NCT07376499
First seen Jan 29, 2026 · Last updated May 22, 2026 · Updated 16 times
Summary
This study tests a maintenance therapy for people with extensive small cell lung cancer that has responded to initial treatment. The combination includes a liposomal form of irinotecan, platinum chemotherapy, an immune checkpoint inhibitor, and anlotinib. The goal is to see if this approach can delay cancer progression and improve survival. About 31 adults will participate.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.